SG11201408487WA - Method for treating a gd2 positive cancer - Google Patents
Method for treating a gd2 positive cancerInfo
- Publication number
- SG11201408487WA SG11201408487WA SG11201408487WA SG11201408487WA SG11201408487WA SG 11201408487W A SG11201408487W A SG 11201408487WA SG 11201408487W A SG11201408487W A SG 11201408487WA SG 11201408487W A SG11201408487W A SG 11201408487WA SG 11201408487W A SG11201408487W A SG 11201408487WA
- Authority
- SG
- Singapore
- Prior art keywords
- treating
- positive cancer
- cancer
- positive
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2012/061618 WO2013189516A1 (en) | 2012-06-18 | 2012-06-18 | Method for treating a gd2 positive cancer |
| PCT/EP2012/064970 WO2013189554A1 (en) | 2012-06-18 | 2012-07-31 | Method for treating a gd2 positive cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201408487WA true SG11201408487WA (en) | 2015-02-27 |
Family
ID=46317406
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408487WA SG11201408487WA (en) | 2012-06-18 | 2012-07-31 | Method for treating a gd2 positive cancer |
| SG10201610532QA SG10201610532QA (en) | 2012-06-18 | 2012-07-31 | Method for treating a gd2 positive cancer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201610532QA SG10201610532QA (en) | 2012-06-18 | 2012-07-31 | Method for treating a gd2 positive cancer |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US10294305B2 (ja) |
| JP (1) | JP6283665B2 (ja) |
| KR (1) | KR101927118B1 (ja) |
| CN (1) | CN104487088A (ja) |
| AP (1) | AP2014008129A0 (ja) |
| AU (1) | AU2012383254B2 (ja) |
| BR (1) | BR112014031806A8 (ja) |
| CA (1) | CA2876529C (ja) |
| EA (1) | EA038188B1 (ja) |
| HK (1) | HK1203375A1 (ja) |
| IL (1) | IL235696A0 (ja) |
| MX (1) | MX2014013858A (ja) |
| SG (2) | SG11201408487WA (ja) |
| WO (2) | WO2013189516A1 (ja) |
| ZA (1) | ZA201407961B (ja) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013189516A1 (en) | 2012-06-18 | 2013-12-27 | Apeiron Biologics Ag | Method for treating a gd2 positive cancer |
| EP4218811A1 (en) | 2012-06-18 | 2023-08-02 | Apeiron Biologics AG | Method for treating a gd2 positive cancer |
| EP3620173A1 (en) | 2013-11-21 | 2020-03-11 | Apeiron Biologics AG | Preparations and methods for treating a gd2 positive cancer |
| US9840566B2 (en) | 2013-11-21 | 2017-12-12 | Apeiron Biologics Ag | Preparations and methods for treating a GD2 positive cancer |
| PT3154583T (pt) * | 2014-06-04 | 2021-03-24 | Biontech Res And Development Inc | Anticorpos monoclonais humanos para o gangliósido gd2 |
| US10329323B2 (en) | 2014-07-25 | 2019-06-25 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Method for purifying antibodies using PBS |
| WO2017055385A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-cd3xgd2 bispecific t cell activating antigen binding molecules |
| EP3596108A4 (en) | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | TARGETED IMMUNOTOLERANCE |
| WO2018217989A1 (en) | 2017-05-24 | 2018-11-29 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| EP3684818A2 (en) * | 2017-09-21 | 2020-07-29 | UMC Utrecht Holding B.V. | Anti-gd2 antibody for the treatment of neuroblastoma |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| CN108948211B (zh) * | 2018-07-24 | 2021-08-20 | 北京美康基免生物科技有限公司 | 一种基于靶向gd2的嵌合抗原受体及其应用 |
| WO2020165402A1 (en) | 2019-02-14 | 2020-08-20 | Westfälische Wilhelms-Universität Münster | Gd2-upregulation by ezh2 inhibition in cancer therapy |
| WO2020236562A1 (en) | 2019-05-17 | 2020-11-26 | Cancer Prevention Pharmaceuticals, Inc. | Methods for treating familial adenomatous polyposis |
| US11739146B2 (en) | 2019-05-20 | 2023-08-29 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
| JP7505784B2 (ja) | 2019-08-01 | 2024-06-25 | 国立大学法人三重大学 | Ｇｄ２結合性分子 |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| US20230295339A1 (en) | 2020-07-06 | 2023-09-21 | Eusa Pharma (Uk) Limited | Method for treating a gd2-positive cancer |
| EP4116330A1 (en) * | 2021-07-05 | 2023-01-11 | Trion Research GmbH | Multispecific antibodies with monovalent binding to tumor-associated antigens causing no or reduced nerve pain in the treatment of cancer |
| JP2024524527A (ja) * | 2021-07-05 | 2024-07-05 | トリオン リサーチ ゲーエムベーハー | がん治療において神経疼痛の消失または軽減をもたらす腫瘍関連抗原に結合する多重特異性抗体 |
| EP4194471A1 (en) * | 2021-12-10 | 2023-06-14 | Y-Mabs Therapeutics, Inc. | Anti-gd2 administration regimen |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4863713A (en) | 1986-06-23 | 1989-09-05 | The Board Of Trustees Of Leland Stanford Jr. Univ. | Method and system for administering therapeutic and diagnostic agents |
| CA2433353C (en) * | 2000-12-28 | 2017-03-21 | Altus Biologics, Inc. | Crystals of whole antibodies and fragments thereof and methods for making and using them |
| US7455833B2 (en) | 2002-07-15 | 2008-11-25 | Board Of Regents, The University Of Texas System | Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
| BRPI0317376B8 (pt) * | 2002-12-17 | 2021-05-25 | Merck Patent Gmbh | proteína de fusão de anticorpo-il2 designada como hu14.18-il2, usos da mesma, vetor e composição farmacêutica |
| DK1706428T3 (da) | 2004-01-22 | 2009-11-30 | Merck Patent Gmbh | Anti-cancer-antistoffer med reduceret komplementfiksering |
| WO2007045465A1 (en) | 2005-10-21 | 2007-04-26 | F. Hoffmann-La Roche Ag | Method for the recombinant expression of a polypeptide |
| EP1916257A1 (en) | 2006-10-27 | 2008-04-30 | Charite-Universitätsmedizin Berlin | GD2 peptide mimotopes for anticancer vaccination |
| CN102164962B (zh) | 2008-06-30 | 2014-05-28 | 诺福泰克公司 | 抗gd2抗体和方法及其相关应用 |
| CN103347894B (zh) * | 2010-06-19 | 2017-05-10 | 纪念斯隆-凯特林癌症中心 | 抗gd2抗体 |
| US8435972B2 (en) * | 2010-09-02 | 2013-05-07 | Emory University | Method for the treatment of central nervous system cancers and compositions related thereto |
| CN118290588A (zh) | 2011-10-27 | 2024-07-05 | 健玛保 | 异二聚体蛋白的生成 |
| EP4218811A1 (en) | 2012-06-18 | 2023-08-02 | Apeiron Biologics AG | Method for treating a gd2 positive cancer |
| WO2013189516A1 (en) | 2012-06-18 | 2013-12-27 | Apeiron Biologics Ag | Method for treating a gd2 positive cancer |
| US9840566B2 (en) * | 2013-11-21 | 2017-12-12 | Apeiron Biologics Ag | Preparations and methods for treating a GD2 positive cancer |
| EP3620173A1 (en) | 2013-11-21 | 2020-03-11 | Apeiron Biologics AG | Preparations and methods for treating a gd2 positive cancer |
-
2012
- 2012-06-18 WO PCT/EP2012/061618 patent/WO2013189516A1/en active Application Filing
- 2012-07-31 JP JP2015517621A patent/JP6283665B2/ja active Active
- 2012-07-31 EA EA201500019A patent/EA038188B1/ru unknown
- 2012-07-31 WO PCT/EP2012/064970 patent/WO2013189554A1/en active Application Filing
- 2012-07-31 SG SG11201408487WA patent/SG11201408487WA/en unknown
- 2012-07-31 AP AP2014008129A patent/AP2014008129A0/xx unknown
- 2012-07-31 KR KR1020147033790A patent/KR101927118B1/ko active IP Right Grant
- 2012-07-31 SG SG10201610532QA patent/SG10201610532QA/en unknown
- 2012-07-31 BR BR112014031806A patent/BR112014031806A8/pt not_active Application Discontinuation
- 2012-07-31 MX MX2014013858A patent/MX2014013858A/es active IP Right Grant
- 2012-07-31 CA CA2876529A patent/CA2876529C/en active Active
- 2012-07-31 AU AU2012383254A patent/AU2012383254B2/en active Active
- 2012-07-31 CN CN201280074061.1A patent/CN104487088A/zh active Pending
-
2014
- 2014-02-18 US US14/182,776 patent/US10294305B2/en active Active
- 2014-10-31 ZA ZA2014/07961A patent/ZA201407961B/en unknown
- 2014-11-13 IL IL235696A patent/IL235696A0/en unknown
-
2015
- 2015-04-23 HK HK15103941.7A patent/HK1203375A1/xx unknown
-
2017
- 2017-09-11 US US15/700,538 patent/US11447565B2/en active Active
-
2019
- 2019-04-04 US US16/375,022 patent/US20200055953A1/en not_active Abandoned
-
2022
- 2022-09-19 US US17/933,295 patent/US20230340148A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US10294305B2 (en) | 2019-05-21 |
| WO2013189516A1 (en) | 2013-12-27 |
| AU2012383254A1 (en) | 2014-11-20 |
| HK1203375A1 (en) | 2015-10-30 |
| WO2013189554A1 (en) | 2013-12-27 |
| BR112014031806A2 (pt) | 2017-08-29 |
| IL235696A0 (en) | 2015-01-29 |
| AP2014008129A0 (en) | 2014-12-31 |
| EA038188B1 (ru) | 2021-07-21 |
| ZA201407961B (en) | 2015-10-28 |
| JP6283665B2 (ja) | 2018-02-21 |
| CN104487088A (zh) | 2015-04-01 |
| SG10201610532QA (en) | 2017-02-27 |
| EA201500019A1 (ru) | 2015-05-29 |
| KR20150030650A (ko) | 2015-03-20 |
| JP2015521607A (ja) | 2015-07-30 |
| CA2876529A1 (en) | 2013-12-27 |
| US11447565B2 (en) | 2022-09-20 |
| AU2012383254B2 (en) | 2017-12-14 |
| BR112014031806A8 (pt) | 2018-01-16 |
| US20180134801A1 (en) | 2018-05-17 |
| US20200055953A1 (en) | 2020-02-20 |
| MX2014013858A (es) | 2015-02-12 |
| CA2876529C (en) | 2023-09-26 |
| US20230340148A1 (en) | 2023-10-26 |
| US20140170155A1 (en) | 2014-06-19 |
| KR101927118B1 (ko) | 2019-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1203375A1 (en) | Method for treating a gd2 positive cancer gd2 | |
| HK1214504A1 (zh) | 用於治療貧血的方法 | |
| IL237791A0 (en) | A method for treating cancer | |
| ZA201501914B (en) | Method for enhancing specific immunotherapies in cancer treatment | |
| SG11201503893RA (en) | Method of treating cancer | |
| ZA201906339B (en) | Methods for treating pruritus | |
| EP2830648A4 (en) | METHODS OF TREATING NEOPLASIA | |
| ZA201407411B (en) | Process for treating biomass | |
| HK1212617A1 (zh) | 白癜風的治療 | |
| EP2895206A4 (en) | METHOD FOR TREATING CARCINOMA | |
| IL228644A0 (en) | Cancer treatment methods | |
| HRP20200128T1 (hr) | Pripreme za liječenje gd2 pozitivnog raka | |
| IL254964A0 (en) | A method for treating breast cancer | |
| ZA201503005B (en) | Ingenol-derived compounds useful for treating cancer | |
| EP2888594A4 (en) | METHOD OF DETERMINING TREATMENT FOR USE AGAINST BREAST CANCER | |
| EP2923374A4 (en) | METHOD FOR TREATING A SEMICONDUCTOR | |
| HK1209040A1 (en) | Methods for treating vestibulotoxicity | |
| SG10201705513YA (en) | Process for treating a structure | |
| AU2012901918A0 (en) | Methods for treating cancer | |
| GB201205449D0 (en) | Treatment process |